{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:46:42Z","timestamp":1790192802516,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Atypical haemolytic uraemic syndrome (aHUS) is a rare systemic syndrome characterized by non-immune haemolytic anaemia, thrombocytopenia, and kidney injury. In most cases, alternative complement pathway dysregulation is the identifying cause. Recently, other genetic causes have been identified, including a mutation in the diacylglycerol kinase epsilon (DGKE) gene, which theoretically affect the coagulation pathway and does not affect the complement pathway. Data about the management of these patients are limited. Ideal management and definitive treatment protocols have not yet been established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A three-year-old boy presented with features of atypical haemolytic uraemic syndrome (aHUS) and low complement C3. He was presumed to have complement-mediated aHUS and was managed empirically with eculizumab. Two weeks after starting eculizumab, his haemoglobin levels, platelet count, and complement C3 level normalized but he continued to have non-nephrotic range proteinuria. His genetic testing revealed a homozygous DGKE mutation, with no other mutation detected. Six months after presentation, the patient was still in remission with no features of aHUS, a trial of weaning eculizumab by increasing dose interval was followed by nephrotic range proteinuria and severe oedema. His proteinuria improved and his oedema resolved after resuming his recommended eculizumab dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>DGKE gene mutation can lead to aHUS with theoretically no complement dysregulation. However, some patients with this mutation show alternative complement pathway activation. This case report describes a patient with aHUS due to a DGKE gene mutation and low C3 levels who responded to eculizumab, adding to the previously reported cases of patients with DGKE gene mutations who had complete remission with no relapse with C5 blockers and\/or plasma exchange. A randomized controlled study on patients with DGKE mutations might be beneficial in understanding the disease and generating a management protocol.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02352-8","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T11:09:37Z","timestamp":1618916977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Muneera","family":"Alabdulqader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alfakeeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"issue":"17","key":"2352_CR1","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical Hemolytic\u2013Uremic Syndrome. N Engl J Med. 2009;361(17):1676\u201387. doi:https:\/\/doi.org\/10.1056\/NEJMra0902814.","journal-title":"N Engl J Med"},{"issue":"5","key":"2352_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","volume":"45","author":"M Lemaire","year":"2013","unstructured":"Lemaire M, Fr\u00e9meaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45(5):531\u20136. doi:https:\/\/doi.org\/10.1038\/ng.2590.","journal-title":"Nat Genet"},{"issue":"3","key":"2352_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1681\/ASN.2012090903","volume":"24","author":"F Ozaltin","year":"2013","unstructured":"Ozaltin F, Li B, Rauhauser A, et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol. 2013;24(3):377\u201384. doi:https:\/\/doi.org\/10.1681\/ASN.2012090903.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2352_CR4","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1681\/ASN.2017010031","volume":"28","author":"K Azukaitis","year":"2017","unstructured":"Azukaitis K, Simkova E, Abdul Majid M, et al. The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol Kinase \u03f5. J Am Soc Nephrol. 2017;28(10):3066\u201375. doi:https:\/\/doi.org\/10.1681\/ASN.2017010031.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2352_CR5","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","volume":"97","author":"V Brocklebank","year":"2020","unstructured":"Brocklebank V, Kumar G, Howie AJ, et al. Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int. 2020;97(6):1260\u201374. doi:https:\/\/doi.org\/10.1016\/j.kint.2020.01.045.","journal-title":"Kidney Int"},{"issue":"9","key":"2352_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2215\/CJN.01640214","volume":"9","author":"DS Chinchilla","year":"2014","unstructured":"Chinchilla DS, Pinto S, Hoppe B, et al. Complement mutations in diacylglycerol kinase-\u025b\u2013associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2014;9(9):1611\u20139. doi:https:\/\/doi.org\/10.2215\/CJN.01640214.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2352_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701\u201311. doi:https:\/\/doi.org\/10.1016\/j.kint.2015.11.026.","journal-title":"Kidney Int"},{"issue":"4","key":"2352_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00467-018-4186-x","volume":"34","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use (Pediatric Nephrology, (2018), 10.1007\/s00467-018-4091-3). Pediatr Nephrol. 2019;34(4):741\u20132. doi:https:\/\/doi.org\/10.1007\/s00467-018-4186-x.","journal-title":"Pediatr Nephrol"},{"key":"2352_CR9","unstructured":"Food and Drug Administration. Alexion briefing information for the November 18, 2014, meeting of the Drug Safety and Risk Management Advisory Committee. https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/DrugSafetyandRiskManagementAdv."},{"issue":"1","key":"2352_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15\u201339. doi:https:\/\/doi.org\/10.1007\/s00467-015-3076-8.","journal-title":"Pediatr Nephrol"},{"key":"2352_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734\u20137. doi:https:\/\/doi.org\/10.15585\/mmwr.mm6627e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2352_CR12","doi-asserted-by":"publisher","unstructured":"Holanda MI, De, Gomes CP, Araujo SDA, et al. Diacylglycerol kinase epsilon nephropathy: late diagnosis and therapeutic implications. 2019;12(5):641\u2013644. doi:https:\/\/doi.org\/10.1093\/ckj\/sfz043.","DOI":"10.1093\/ckj\/sfz043"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02352-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02352-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02352-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T11:32:23Z","timestamp":1618918343000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02352-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2352"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02352-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this was a case report in which the patient was not identified, the requirement for ethical approval was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent for publication was obtained from the parents of the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There were no financial or non-financial competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}